CORT Financial Facts

Total operating expenses: 13.16M
Research and development: 3.61M
See Full Income Statement

Additional paid-in capital: 344.74M
Commitments: 0
See Full Balance Sheet

Corcept Therapeutics (CORT) Earnings

  |   Expand Research on CORT
Next EPS Date 5/6/16 *Est. EPS Growth Rate +150.0% *Last Qtr.
Average EPS % Beat Rate +56.3% Revenue Growth Rate +66.5% *Last Qtr.
Average % Move 1-Wk after EPS +8.2% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/7/13 Q313 -$0.08-$0.12 +$0.04$2.6M$2.7M N/A Details
8/8/13 Q213 -$0.10-$0.11 +$0.01$1.9M$2.72M N/A Details
8/7/12 Q212 -$0.09-$0.11 +$0.02N/AN/A N/A Details
5/3/12 Q112 -$0.13-$0.11 -$0.02N/AN/A N/A Details
3/5/14 Q413 -$0.11-$0.10 -$0.01$4.1M$4.01M N/A Details
11/10/10 Q310 -$0.10-$0.10 $0.00N/AN/A N/A Details
3/9/11 Q410 -$0.10-$0.10 $0.00N/A$120K N/A Details
5/4/11 Q111 -$0.09-$0.10 +$0.01N/AN/A N/A Details